FDA User Fee Bill: House Cmte. Makes Technical Changes, Adds Pricing Resolution

House Energy and Commerce Committee refines FDA Reauthorization Act and adopts a ‘sense of Congress’ resolution on drug pricing, but largely steers clear of other potentially controversial add-ons that could bog down the measure.

Capitol House

The House Energy and Commerce’s mark-up of user fee legislation for the US FDA on June 7 reflects lawmakers’ ongoing, laser-like focus on ensuring the key funding measure for the agency’s medical product review programs does not get bogged down in controversy.

The amended version of the FDA Reauthorization Act (FDARA) that passed the full committee on a 54-0 vote looks very...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legislation

More from Pink Sheet